Skip to main content

Advertisement

SpringerLink
Log in

Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Yeh JJ, Weiser MR, Shia J, Hwu WJ. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol. 2005;6(6):438–9.

    Article  PubMed  Google Scholar 

  2. Natarajan N, Telang S, Miller D, Chesney J. Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs. 2011;71(10):1233–50.

    Article  PubMed  CAS  Google Scholar 

  3. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327–34.

    Article  PubMed  CAS  Google Scholar 

  4. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. Erratum, N Engl J Med 2010; 363:1290.

    Article  PubMed  CAS  Google Scholar 

  5. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.

    Article  PubMed  CAS  Google Scholar 

  6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    Article  PubMed  CAS  Google Scholar 

  7. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation-positive melanoma. J Clin Oncol. 2011;29(Suppl):8509. Abstract.

    Google Scholar 

  8. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340–6.

    Article  PubMed  CAS  Google Scholar 

  9. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer. 2007;121(2):257–64.

    Article  PubMed  CAS  Google Scholar 

  10. McDonnell K, Betz B, Fullen D, Lao CD. V559A and N822I double KIT mutant melanoma with predictable response to imatinib? Pigment Cell Melanoma Res. 2011;24(2):390–2.

    Article  PubMed  Google Scholar 

  11. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 2008;21(4):492–3.

    Article  PubMed  Google Scholar 

  12. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer. 2005;92(8):1398–405.

    Article  PubMed  CAS  Google Scholar 

  13. Atkins MB, Prieto V. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma significant toxicity with no clinical efficacy. Cancer. 2006;106(9):2005–11.

    Article  PubMed  Google Scholar 

  14. Woodman SE, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol. 2010;80(5):568–74.

    Article  PubMed  CAS  Google Scholar 

  15. Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res. 2009;15(24):7510–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Competing interests

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, National Institute of Medical Oncology, Rabat, Morocco

    Samia Arifi, El Mehdi Tazi & Hassan Errihani

  2. Department of Medical Oncology, Hassan II University Hospital, Route Sidi Harazem, 30000, Fez, Morocco

    Samia Arifi & Omar El Mesbahi

Authors
  1. Samia Arifi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. El Mehdi Tazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omar El Mesbahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hassan Errihani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samia Arifi.

Additional information

Consent

Written informed consent was obtained from the patient(s) for publication of this manuscript and accompanying images.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arifi, S., Tazi, E.M., El Mesbahi, O. et al. Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report. J Gastrointest Canc 43 (Suppl 1), 145–147 (2012). https://doi.org/10.1007/s12029-011-9340-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-011-9340-7

Keywords

Search

Navigation